Langerhans Cell Histiocytosis

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

FP
Fosun PharmaAustralia - Sydney
1 program
1
FCN-159Phase 21 trial
Active Trials
NCT05997602Recruiting56Est. May 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
Fosun PharmaFCN-159

Clinical Trials (1)

Total enrollment: 56 patients across 1 trials

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Start: Sep 2023Est. completion: May 202756 patients
Phase 2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 56 patients
1 companies competing in this space